Elanco Animal Health (NYSE:ELAN) Announces FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 1.170-1.200 for the period, compared to the consensus estimate of 1.130. The company issued revenue guidance of $5.2 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q4 2026 guidance to 0.160-0.190 EPS.

Analyst Ratings Changes

Several equities analysts have commented on ELAN shares. The Goldman Sachs Group started coverage on Elanco Animal Health in a research report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective for the company. Jefferies Financial Group downgraded shares of Elanco Animal Health from a “buy” rating to a “hold” rating and reduced their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. UBS Group increased their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Morgan Stanley decreased their price target on shares of Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. Finally, Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.33.

Elanco Animal Health Stock Up 8.2%

Shares of Elanco Animal Health stock traded up $1.95 during midday trading on Friday, hitting $25.63. The company had a trading volume of 4,890,442 shares, compared to its average volume of 5,591,565. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The stock has a market capitalization of $12.81 billion, a P/E ratio of -62.38, a P/E/G ratio of 2.25 and a beta of 1.73. The company has a 50 day moving average of $23.11 and a 200 day moving average of $23.82. Elanco Animal Health has a 52-week low of $19.40 and a 52-week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%. The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, equities analysts predict that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Lawrence Kurzius purchased 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was purchased at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. The trade was a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Shiv O’Neill purchased 3,998 shares of the stock in a transaction dated Tuesday, August 18th. The stock was bought at an average cost of $23.58 per share, with a total value of $94,272.84. Following the transaction, the insider owned 87,832 shares in the company, valued at $2,071,078.56. The trade was a 4.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 48,998 shares of company stock valued at $1,139,373 over the last ninety days. Insiders own 1.14% of the company’s stock.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS of $0.27 topped the $0.20 consensus estimate, and revenue of $1.265 billion exceeded expectations of about $1.21 billion. Revenue rose 11% year over year, with 9% organic constant-currency growth. Elanco third-quarter results
• Positive Sentiment: Elanco raised 2026 adjusted EPS guidance to $1.17–$1.20, above the $1.13 consensus, and lifted revenue guidance to $5.155–$5.18 billion versus approximately $5.1 billion expected. It also increased its innovation revenue target and improved its year-end net leverage target to about 2.9x adjusted EBITDA. Elanco third-quarter results
• Positive Sentiment: Company survey results suggest resilient consumer demand: 93% of surveyed pet owners maintained or increased pet spending over the prior three months, supporting the outlook for pet-health products. Elanco consumer research
• Neutral Sentiment: Fourth-quarter revenue guidance of $1.2 billion matches consensus. EPS guidance of $0.16–$0.19 has a midpoint of $0.175, just below the $0.18 estimate, though the range includes consensus. Elanco third-quarter results

About Elanco Animal Health

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites and support the health and productivity of animals.

The company’s products include vaccines, parasiticides, antibiotics, nutritional supplements and other prescription and over-the-counter therapies. Its companion animal offerings address conditions such as flea and tick infestations, internal parasites, osteoarthritis and dermatological disorders, while its farm animal products support the health of cattle, poultry, swine and aquaculture species.

Elanco serves customers in markets around the world through relationships with veterinarians, animal owners, livestock producers, retailers and distributors.